Brain zapping trial aims to fix sensory confusion in schizophrenia
NCT ID NCT07632261
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a personalized brain stimulation technique called HD-tACS to help people with schizophrenia better combine information from their senses. The treatment is tailored to each patient's brain activity and targets areas involved in sensory binding. The trial will include 80 participants and aims to reduce perceptual distortions, potentially easing a core symptom of the disorder.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 80 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria for control group and patient: * Be aged 18 to 65 years inclusive. * Have read and understood the study information sheet. * Be affiliated with a social security system or be a beneficiary. * Have normal or corrected-to-normal vision (glasses or contact lenses). Exclusion Criteria for control group : * Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field. * Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.) * Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.) * Legal incapacity (under guardianship, conservatorship, or judicial/administrative detention) or inability to provide informed consent. * Major psychiatric disorders (excluding tobacco use disorder). * Neurological disorders. * Severe somatic disorders that could interfere with participation. * Uncorrected visual impairments. * Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.). * Presence of any psychiatric disorder. * Under legal protection (guardianship or conservatorship). Exclusion Criteria - Patient Group A potential patient participant will be excluded if they have: * Any contraindication to tACS, e.g., cardiac pacemaker or other devices that could interfere with the electric field. * Any contraindication to MRI, e.g., neurological stimulator, pacemaker, cardiac defibrillator, cardiac or vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid shunt, metallic fragments in the eyes, cochlear implants, severe claustrophobia. (A standardized MRI screening questionnaire will be provided.) * Pregnancy or breastfeeding. (Pregnancy status will be verified with a test on the day of the exam.) * Legal incapacity (under guardianship, conservatorship, or judicial/administrative detention) or inability to provide informed consent. * Major psychiatric disorders other than schizophrenia (excluding tobacco use disorder). * Neurological disorders. * Severe somatic disorders that could interfere with participation. * Uncorrected visual impairments. * Recent consumption of substances likely to alter brain activity (alcohol, drugs, etc.).
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists build a computer model of the brain to explain hearing voices
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug